Bruker Co. (NASDAQ:BRKR) Receives $70.50 Average Target Price from Brokerages

Bruker Co. (NASDAQ:BRKR) has earned an average rating of “Moderate Buy” from the eleven research firms that are covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $70.50.

BRKR has been the subject of a number of research analyst reports. Barclays reduced their price target on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating for the company in a research note on Monday, February 10th. UBS Group assumed coverage on Bruker in a research note on Tuesday, December 10th. They issued a “neutral” rating and a $66.00 price target on the stock. Stifel Nicolaus dropped their price target on Bruker from $70.00 to $57.00 and set a “hold” rating on the stock in a research note on Friday, February 14th. Bank of America raised their price target on Bruker from $78.00 to $80.00 and gave the stock a “buy” rating in a research note on Friday, December 13th. Finally, Guggenheim restated a “buy” rating on shares of Bruker in a research note on Monday, February 24th.

Bruker Stock Up 2.2 %

NASDAQ:BRKR opened at $45.97 on Thursday. The firm has a market cap of $6.97 billion, a P/E ratio of 60.49, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.77 and a current ratio of 1.60. Bruker has a fifty-two week low of $44.11 and a fifty-two week high of $94.86. The firm has a 50-day simple moving average of $53.66 and a two-hundred day simple moving average of $58.40.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 earnings per share for the quarter, beating analysts’ consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Analysts predict that Bruker will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Monday, March 17th will be given a dividend of $0.05 per share. The ex-dividend date is Monday, March 17th. This represents a $0.20 annualized dividend and a yield of 0.44%. Bruker’s dividend payout ratio (DPR) is presently 26.32%.

Institutional Investors Weigh In On Bruker

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Gordian Capital Singapore Pte Ltd bought a new stake in Bruker during the fourth quarter valued at about $234,000. EDENTREE ASSET MANAGEMENT Ltd raised its holdings in Bruker by 11.2% during the fourth quarter. EDENTREE ASSET MANAGEMENT Ltd now owns 158,000 shares of the medical research company’s stock valued at $9,262,000 after acquiring an additional 15,900 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Bruker by 17.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 356,969 shares of the medical research company’s stock valued at $20,926,000 after acquiring an additional 52,214 shares during the period. Voloridge Investment Management LLC raised its holdings in Bruker by 179.6% during the fourth quarter. Voloridge Investment Management LLC now owns 18,906 shares of the medical research company’s stock valued at $1,108,000 after acquiring an additional 12,145 shares during the period. Finally, Two Sigma Advisers LP raised its holdings in Bruker by 406.1% during the fourth quarter. Two Sigma Advisers LP now owns 140,700 shares of the medical research company’s stock valued at $8,248,000 after acquiring an additional 112,900 shares during the period. 79.52% of the stock is owned by institutional investors.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.